Halozyme Therapeutics Inc (HALO)

Operating profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	337,574	311,048	306,061	245,663	267,531	249,556	241,850	300,837	275,902	296,992	261,705	198,213	144,255	34,569	-30,267	-73,799	-67,610	-35,619	-36,556	-42,652
Revenue (ttm)	US$ in thousands	810,397	762,509	752,443	685,200	643,040	566,152	478,768	464,176	435,810	457,564	408,802	329,314	267,594	199,556	180,470	164,397	195,992	202,559	181,885	177,939
Operating profit margin		41.66%	40.79%	40.68%	35.85%	41.60%	44.08%	50.52%	64.81%	63.31%	64.91%	64.02%	60.19%	53.91%	17.32%	-16.77%	-44.89%	-34.50%	-17.58%	-20.10%	-23.97%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $337,574K ÷ $810,397K
= 41.66%

Halozyme Therapeutics Inc.'s operating profit margin has shown fluctuations over the past eight quarters. In Q1 2022, the operating profit margin was highest at 63.80%, suggesting strong operational efficiency and profitability. However, there has been a decreasing trend thereafter, with Q4 2023 recording a margin of 40.71%.

The variability in operating profit margins indicates potential changes in cost structures, pricing strategies, or operational efficiencies within the company. Despite the fluctuations, Halozyme Therapeutics Inc. has maintained relatively healthy operating profit margins above 30% throughout the period under review.

Further analysis of the factors contributing to the changes in operating profit margin over the quarters could provide insights into the company's financial performance and management effectiveness in controlling costs and generating revenues.